Clinical Trial Update: Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating pharmacokinetics, safety and tolerability of intravenous secukinumab in pediatric participants with Juvenile Psoriatic Arthritis, cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Psoriatic Arthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Juvenile Psoriatic Arthritis | Phase 1 | Status: RECRUITING